Insulin lispro (ultra rapid formulation) - Eli lilly

Drug Profile

Insulin lispro (ultra rapid formulation) - Eli lilly

Alternative Names: LY-900014

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase I Diabetes mellitus

Most Recent Events

  • 07 Jun 2017 Phase-III clinical trials in Type-2 diabetes mellitus in Slovakia, Hungary (SC) (EudraCT2015-005357-12)
  • 30 May 2017 Phase-III clinical trials in Type-1 diabetes mellitus (Combination therapy) in Austria (SC) (EudraCT2015-005356-99)
  • 26 May 2017 Eli Lilly plans a phase I trial for Type-1 Diabetes mellitus in Germany (NCT03166124)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top